Who is affected by this change?

This affects Independence Blue Cross Endocrinology, Ophthalmology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Oct 1, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.115c, Teprotumumab (Tepezza®)

Independence Blue Cross·Endocrinology, Ophthalmology·Pharmacy

Effective date

Oct 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a Medicare Advantage notification regarding Teprotumumab (Tepezza®) policy MA08.115c that became effective October 1, 2025. The notification indicates a policy change for this thyroid eye disease medication, though specific details about coverage or billing requirements are not provided in the summary.

Action Required

Action needed

Immediately: Billing team should access the full policy document at the provided URL to review specific changes to Teprotumumab (Tepezza®) coverage requirements for Medicare Advantage plans. Update billing procedures and prior authorization workflows as needed based on the complete policy details.

Related policy hubs

Independence Blue Cross policies Endocrinology Ophthalmology